{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HER2+directed+therapy&page=2", "query": { "intervention": "HER2 directed therapy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HER2+directed+therapy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T08:40:12.975Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04143711", "title": "Study of DF1001 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "DF1001", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dragonfly Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2019-11-11", "completion_date": "2025-12-05", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-09-28T08:40:12.975Z", "location_count": 16, "location_summary": "Irvine, California • Los Angeles, California • San Diego, California + 13 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04143711" }, { "nct_id": "NCT03387553", "title": "HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer", "Breast Cancer Female", "Breast Cancer, Male", "Invasive Breast Cancer", "HER2-positive Breast Cancer", "HER2 Positive Breast Carcinoma", "Stage II Breast Cancer", "Stage III Breast Cancer" ], "interventions": [ { "name": "Dendritic Cell Vaccine (DC1)", "type": "BIOLOGICAL" }, { "name": "Neoadjuvant Chemotherapy", "type": "DRUG" }, { "name": "Curative Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2018-06-06", "completion_date": "2026-02-19", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-09-28T08:40:12.975Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03387553" }, { "nct_id": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Colon Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Esophageal Carcinoma", "Exocrine Pancreas Carcinoma", "Gastric Carcinoma", "Glioma", "Head and Neck Carcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Kidney Carcinoma", "Liver Carcinoma", "Lung Carcinoma", "Lymphoma", "Malignant Uterine Corpus Neoplasm", "Malignant Uterine Neoplasm", "Melanoma", "Multiple Myeloma", "Ovarian Carcinoma", "Prostate Carcinoma", "Rectal Carcinoma", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Colon Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Glioma", "Recurrent Head and Neck Carcinoma", "Recurrent Liver Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Malignant Uterine Corpus Neoplasm", "Recurrent Melanoma", "Recurrent Multiple Myeloma", "Recurrent Ovarian Carcinoma", "Recurrent Pancreatic Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Rectal Carcinoma", "Recurrent Skin Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma", "Skin Carcinoma", "Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Afatinib Dimaleate", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Defactinib", "type": "DRUG" }, { "name": "Defactinib Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Fexagratinib", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Larotrectinib", "type": "DRUG" }, { "name": "Larotrectinib Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "PI3K-beta Inhibitor GSK2636771", "type": "DRUG" }, { "name": "Radiologic Examination", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Taselisib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6452, "start_date": "2015-08-17", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-28T08:40:12.975Z", "location_count": 1405, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02465060" }, { "nct_id": "NCT00095706", "title": "Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Bevacizumab (drug), Herceptin (drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Translational Oncology Research International", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 50, "start_date": "2003-06", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2015-09-25", "last_synced_at": "2026-09-28T08:40:12.975Z", "location_count": 18, "location_summary": "Alhambra, California • Bakersfield, California • Fullerton, California + 14 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00095706" }, { "nct_id": "NCT01796197", "title": "Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mastectomy", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2013-08", "completion_date": "2026-01", "has_results": true, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-09-28T08:40:12.975Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01796197" }, { "nct_id": "NCT05868226", "title": "PRE-ISPY Phase I/II Oncology Platform Program", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Metastatic Cancer", "Metastatic Breast Cancer", "Metastatic", "HER2-positive Metastatic Breast Cancer", "HER2 Mutation-Related Tumors", "HER-2 Protein Overexpression", "HER2-negative Breast Cancer", "Triple Negative Breast Cancer", "HR Positive", "Hormone Receptor-positive Breast Cancer", "Estrogen Receptor Positive Tumor", "Progesterone Receptor-positive Breast Cancer", "Hormone Receptor Negative Breast Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "Solid Carcinoma", "HER2 Low Breast Cancer", "HER2 Low Breast Carcinoma", "ER Positive Breast Cancer", "PR-positive Breast Cancer", "Minimal Residual Disease", "Colo-rectal Cancer", "Colon Cancer", "Rectal Cancer", "ctDNA Monitoring", "Colorectal Neoplasms", "Colonic Neoplasms", "Rectal Neoplasms", "Neoplasm, Residual", "Adenocarcinoma of Colon", "Adenocarcinoma" ], "interventions": [ { "name": "ALX148", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "TTX-MC138", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2023-02-15", "completion_date": "2031-12-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-28T08:40:12.975Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05868226" }, { "nct_id": "NCT06055881", "title": "Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Carcinoma", "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Surveys", "type": "OTHER" }, { "name": "Stereotactic Body Radiation Therapy (SBRT)", "type": "RADIATION" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 45, "start_date": "2023-10-23", "completion_date": "2031-08-06", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-28T08:40:12.975Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06055881" }, { "nct_id": "NCT01304784", "title": "A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER-2 Gene Amplification" ], "interventions": [ { "name": "Cisplatin, Capecitabine, Trastuzumab and MM-111", "type": "DRUG" }, { "name": "Lapatinib +/- Trastuzumab and MM-111", "type": "DRUG" }, { "name": "Paclitaxel, Trastuzumab and MM-111", "type": "DRUG" }, { "name": "Lapatinib, trastuzumab, paclitaxel, and MM-111", "type": "DRUG" }, { "name": "Docetaxel, trastuzumab and MM-111", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2011-01", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2015-12-16", "last_synced_at": "2026-09-28T08:40:12.975Z", "location_count": 15, "location_summary": "Denver, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 12 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01304784" }, { "nct_id": "NCT01924351", "title": "HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer With Brain Metastasis" ], "interventions": [ { "name": "Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-02", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2020-03-18", "last_synced_at": "2026-09-28T08:40:12.975Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01924351" }, { "nct_id": "NCT07262138", "title": "Active Surveillance in Older Women With ER+ Breast Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Early Stage Estrogen Receptor (ER) Positive Breast Cancer" ], "interventions": [ { "name": "Active Surveillance", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "FEMALE", "summary": "70 Years and older · Female only" }, "enrollment_count": 50, "start_date": "2025-11-01", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-28T08:40:12.975Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07262138" } ] }